{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T12:56:43Z","timestamp":1793451403829,"version":"4.5.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Cangrelor, the first intravenous P2Y\n                    <jats:sub>12<\/jats:sub>\n                    inhibitor (P2Y\n                    <jats:sub>12<\/jats:sub>\n                    -I), has been approved on the basis of three large RCTs from the CHAMPION program which nevertheless have been criticized for the low bleeding risk of the enrolled patients, the large quote of chronic coronary syndromes, and the use of Clopidogrel as control arm even in the setting of acute coronary syndromes (ACS). We sought to investigate, in the setting of ACS, the comparative performance of Cangrelor in terms of in-hospital ischemic and haemorrhagic outcomes compared with the current gold-standard of oral P2Y\n                    <jats:sub>12<\/jats:sub>\n                    -I. The study retrospectively enrolled 686 consecutive patients admitted to the Divisions of Cardiology of Policlinico of Bari and L. Bonomo Hospital of Andria for ACS and treated with percutaneous coronary intervention. The study population was divided according to the P2Y\n                    <jats:sub>12<\/jats:sub>\n                    -I treatment strategy in two groups: patients given an oral P2Y\n                    <jats:sub>12<\/jats:sub>\n                    -I and patients receiving Cangrelor in the cath lab followed by an oral P2Y\n                    <jats:sub>12<\/jats:sub>\n                    -I. Clinical endpoints included death, ischemic and bleeding events occurring during hospital stay. Cangrelor treated patients presented higher clinical risk profile at presentation and faced higher death rate. However, after PS matching, in-hospital mortality resulted comparable between the groups and Cangrelor use was associated with reduced in-hospital definite stent thrombosis (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.03). Data from our real-world registry highlight that, in the setting of ACS, Cangrelor is prevalently used in patients with very challenging clinical presentations. The adjusted analysis provides for the first time promising data on stent thrombosis reduction associated with Cangrelor use.\n                  <\/jats:p>","DOI":"10.1038\/s41598-023-37084-2","type":"journal-article","created":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T11:01:49Z","timestamp":1688209309000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Comparative effectiveness of Cangrelor in patients with acute coronary syndrome undergoing percutaneous coronary intervention: an observational investigation from the M.O.Ca. registry"],"prefix":"10.1038","volume":"13","author":[{"given":"Martino","family":"Pepe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenio","family":"Carulli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Larosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluigi","family":"Napoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Palma Luisa","family":"Nestola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Cristina","family":"Carella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Giordano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rocco","family":"Tritto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Bartolomucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Plinio","family":"Cirillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe Biondi","family":"Zoccai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arturo","family":"Giordano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco Matteo","family":"Ciccone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,1]]},"reference":[{"key":"37084_CR1","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1093\/eurheartj\/ehaa575","volume":"42","author":"JP Collet","year":"2021","unstructured":"Collet, J. P. et al. 2020 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur. Heart J. 42, 1289\u20131367. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa575 (2021).","journal-title":"Eur. Heart J."},{"key":"37084_CR2","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","volume":"39","author":"B Ibanez","year":"2018","unstructured":"Ibanez, B. et al. 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur. Heart J. 39, 119\u2013177. https:\/\/doi.org\/10.1093\/eurheartj\/ehx393 (2018).","journal-title":"Eur. Heart J."},{"key":"37084_CR3","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.amjcard.2019.04.015","volume":"124","author":"M Pepe","year":"2019","unstructured":"Pepe, M. et al. Comparative effectiveness and safety of polymer-free biolimus-eluting stent and durable polymer everolimus-eluting stent in all-comer patients who underwent percutaneous coronary interventions. Am. J. Cardiol. 124, 195\u2013204. https:\/\/doi.org\/10.1016\/j.amjcard.2019.04.015 (2019).","journal-title":"Am. J. Cardiol."},{"key":"37084_CR4","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","volume":"39","author":"M Valgimigli","year":"2018","unstructured":"Valgimigli, M. et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The task force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur. Heart J. 39, 213\u2013260. https:\/\/doi.org\/10.1093\/eurheartj\/ehx419 (2018).","journal-title":"Eur. Heart J."},{"key":"37084_CR5","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1177\/1074248417715004","volume":"23","author":"D Alexopoulos","year":"2018","unstructured":"Alexopoulos, D., Pappas, C., Sfantou, D. & Lekakis, J. Cangrelor in percutaneous coronary intervention: Current status and perspectives. J. Cardiovasc. Pharmacol. Ther. 23, 13\u201322. https:\/\/doi.org\/10.1177\/1074248417715004 (2018).","journal-title":"J. Cardiovasc. Pharmacol. Ther."},{"key":"37084_CR6","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1002\/ccd.27863","volume":"93","author":"M Pepe","year":"2019","unstructured":"Pepe, M. et al. Time-dependent benefits of pre-treatment with new oral P2Y(12) -inhibitors in patients addressed to primary PCI for acute ST-elevation myocardial infarction. Catheter. Cardiovasc. Interv. 93, 592\u2013601. https:\/\/doi.org\/10.1002\/ccd.27863 (2019).","journal-title":"Catheter. Cardiovasc. Interv."},{"key":"37084_CR7","doi-asserted-by":"publisher","first-page":"2330","DOI":"10.1056\/NEJMoa0908629","volume":"361","author":"DL Bhatt","year":"2009","unstructured":"Bhatt, D. L. et al. Intravenous platelet blockade with Cangrelor during PCI. N. Engl. J. Med. 361, 2330\u20132341. https:\/\/doi.org\/10.1056\/NEJMoa0908629 (2009).","journal-title":"N. Engl. J. Med."},{"key":"37084_CR8","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1056\/NEJMoa1300815","volume":"368","author":"DL Bhatt","year":"2013","unstructured":"Bhatt, D. L. et al. Effect of platelet inhibition with Cangrelor during PCI on ischemic events. N. Engl. J. Med. 368, 1303\u20131313. https:\/\/doi.org\/10.1056\/NEJMoa1300815 (2013).","journal-title":"N. Engl. J. Med."},{"key":"37084_CR9","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1016\/j.jcin.2016.06.046","volume":"9","author":"J Abtan","year":"2016","unstructured":"Abtan, J. et al. Efficacy and safety of Cangrelor in preventing periprocedural complications in patients with stable angina and acute coronary syndromes undergoing percutaneous coronary intervention: The CHAMPION PHOENIX trial. JACC Cardiovasc. Interv. 9, 1905\u20131913. https:\/\/doi.org\/10.1016\/j.jcin.2016.06.046 (2016).","journal-title":"JACC Cardiovasc. Interv."},{"key":"37084_CR10","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1093\/eurheartj\/ehs215","volume":"33","author":"ATF Members","year":"2012","unstructured":"Members, A. T. F. et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The task force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). Eur. Heart J. 33, 2569\u20132619. https:\/\/doi.org\/10.1093\/eurheartj\/ehs215 (2012).","journal-title":"Eur. Heart J."},{"key":"37084_CR11","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1056\/nejm199309023291001","volume":"329","author":"Gusto Investigators","year":"1993","unstructured":"Gusto Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N. Engl. J. Med. 329, 673\u2013682. https:\/\/doi.org\/10.1056\/nejm199309023291001 (1993).","journal-title":"N. Engl. J. Med."},{"key":"37084_CR12","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/s0140-6736(09)60738-8","volume":"374","author":"JL Mega","year":"2009","unstructured":"Mega, J. L. et al. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): A randomised, double-blind, phase II trial. Lancet 374, 29\u201338. https:\/\/doi.org\/10.1016\/s0140-6736(09)60738-8 (2009).","journal-title":"Lancet"},{"key":"37084_CR13","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","volume":"3","author":"S Schulman","year":"2005","unstructured":"Schulman, S. & Kearon, C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J. Thromb. Haemost. 3, 692\u2013694. https:\/\/doi.org\/10.1111\/j.1538-7836.2005.01204.x (2005).","journal-title":"J. Thromb. Haemost."},{"key":"37084_CR14","doi-asserted-by":"publisher","first-page":"2736","DOI":"10.1161\/circulationaha.110.009449","volume":"123","author":"R Mehran","year":"2011","unstructured":"Mehran, R. et al. Standardized bleeding definitions for cardiovascular clinical trials: A consensus report from the Bleeding Academic Research Consortium. Circulation 123, 2736\u20132747. https:\/\/doi.org\/10.1161\/circulationaha.110.009449 (2011).","journal-title":"Circulation"},{"key":"37084_CR15","doi-asserted-by":"publisher","first-page":"e618","DOI":"10.1161\/cir.0000000000000617","volume":"138","author":"K Thygesen","year":"2018","unstructured":"Thygesen, K. et al. Fourth universal definition of myocardial infarction (2018). Circulation 138, e618\u2013e651. https:\/\/doi.org\/10.1161\/cir.0000000000000617 (2018).","journal-title":"Circulation"},{"key":"37084_CR16","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1016\/j.ahj.2012.02.018","volume":"163","author":"S Leonardi","year":"2012","unstructured":"Leonardi, S. et al. Rationale and design of the Cangrelor versus standard therapy to acHieve optimal management of platelet InhibitiON PHOENIX trial. Am. Heart J. 163, 768-776.e762. https:\/\/doi.org\/10.1016\/j.ahj.2012.02.018 (2012).","journal-title":"Am. Heart J."},{"key":"37084_CR17","doi-asserted-by":"publisher","first-page":"2632","DOI":"10.1093\/eurheartj\/ehz372","volume":"40","author":"P Urban","year":"2019","unstructured":"Urban, P. et al. Defining high bleeding risk in patients undergoing percutaneous coronary intervention: A consensus document from the Academic Research Consortium for high bleeding risk. Eur. Heart J. 40, 2632\u20132653. https:\/\/doi.org\/10.1093\/eurheartj\/ehz372 (2019).","journal-title":"Eur. Heart J."},{"key":"37084_CR18","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1016\/s0140-6736(17)30397-5","volume":"389","author":"F Costa","year":"2017","unstructured":"Costa, F. et al. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: A pooled analysis of individual-patient datasets from clinical trials. Lancet 389, 1025\u20131034. https:\/\/doi.org\/10.1016\/s0140-6736(17)30397-5 (2017).","journal-title":"Lancet"},{"key":"37084_CR19","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1056\/NEJMoa067731","volume":"356","author":"L Mauri","year":"2007","unstructured":"Mauri, L. et al. Stent thrombosis in randomized clinical trials of drug-eluting stents. N. Engl. J. Med. 356, 1020\u20131029. https:\/\/doi.org\/10.1056\/NEJMoa067731 (2007).","journal-title":"N. Engl. J. Med."},{"key":"37084_CR20","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1016\/j.jacc.2016.07.760","volume":"68","author":"G Giustino","year":"2016","unstructured":"Giustino, G. et al. Efficacy and safety of dual antiplatelet therapy after complex PCI. J. Am. Coll. Cardiol. 68, 1851\u20131864. https:\/\/doi.org\/10.1016\/j.jacc.2016.07.760 (2016).","journal-title":"J. Am. Coll. Cardiol."},{"key":"37084_CR21","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1016\/j.amjcard.2019.08.015","volume":"124","author":"M Pepe","year":"2019","unstructured":"Pepe, M. et al. Impact of insulin-treated and noninsulin-treated diabetes mellitus in all-comer patients undergoing percutaneous coronary interventions with polymer-free biolimus-eluting stent (from the RUDI-FREE registry). Am. J. Cardiol. 124, 1518\u20131527. https:\/\/doi.org\/10.1016\/j.amjcard.2019.08.015 (2019).","journal-title":"Am. J. Cardiol."},{"key":"37084_CR22","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1016\/j.jdiacomp.2018.05.015","volume":"32","author":"M Pepe","year":"2018","unstructured":"Pepe, M. et al. Role of plasma glucose level on myocardial perfusion in ST-segment elevation myocardial infarction patients. J. Diabet. Compl. 32, 764\u2013769. https:\/\/doi.org\/10.1016\/j.jdiacomp.2018.05.015 (2018).","journal-title":"J. Diabet. Compl."},{"key":"37084_CR23","doi-asserted-by":"publisher","first-page":"9","DOI":"10.23736\/s0031-0808.21.04437-2","volume":"64","author":"M Pepe","year":"2022","unstructured":"Pepe, M. et al. Clinical use of cangrelor: A real-world multicenter experience from South Italy. Panminerva Med. 64, 9\u201316. https:\/\/doi.org\/10.23736\/s0031-0808.21.04437-2 (2022).","journal-title":"Panminerva Med."},{"key":"37084_CR24","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1093\/ehjcvp\/pvz002","volume":"5","author":"P Grimfj\u00e4rd","year":"2019","unstructured":"Grimfj\u00e4rd, P., Lagerqvist, B., Erlinge, D., Varenhorst, C. & James, S. Clinical use of Cangrelor: Nationwide experience from the Swedish coronary angiography and angioplasty registry (SCAAR). Eur. Heart J. Cardiovasc. Pharmacother. 5, 151\u2013157. https:\/\/doi.org\/10.1093\/ehjcvp\/pvz002 (2019).","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"key":"37084_CR25","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1016\/s0140-6736(13)61615-3","volume":"382","author":"PG Steg","year":"2013","unstructured":"Steg, P. G. et al. Effect of Cangrelor on periprocedural outcomes in percutaneous coronary interventions: A pooled analysis of patient-level data. Lancet 382, 1981\u20131992. https:\/\/doi.org\/10.1016\/s0140-6736(13)61615-3 (2013).","journal-title":"Lancet"},{"key":"37084_CR26","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1002\/clc.23878","volume":"45","author":"L De Luca","year":"2022","unstructured":"De Luca, L. et al. Use of Cangrelor in patients with acute coronary syndromes undergoing percutaneous coronary intervention: Study design and interim analysis of the ARCANGELO study. Clin. Cardiol. 45, 913\u2013920. https:\/\/doi.org\/10.1002\/clc.23878 (2022).","journal-title":"Clin. Cardiol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-37084-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-37084-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-37084-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T11:03:18Z","timestamp":1688209398000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-37084-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,1]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["37084"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-37084-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2393589\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,1]]},"assertion":[{"value":"19 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Giuseppe Biondi-Zoccai has consulted for Amarin,\u00a0Balmed, Cardionovum, Crannmedical,\u00a0Endocore Lab, Eukon, Guidotti,\u00a0Innovheart, Meditrial, Microport, Opsens Medical, Terumo, and Translumina. All other authors report no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10685"}}